Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the ...

assistant professor at Emory Eye CenterArticles ASRS 2025: Outcomes in patients with noninfectious uveitis requiring secondary lens implantation Sruthi Arepalli, MD; Martin David Harp; Sydney M Crago ...

Panelists discuss how they present the modest efficacy of geographic atrophy (GA) therapies to patients by framing treatment as maintenance therapy that slows progression rather than providing ...

The role of anesthetics in streamlining efficiency and elevating patient care.

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

Retina Group of WashingtonLai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

EP: 4. Choosing Between the Currently Available GA Therapies Therapy selection between the 2 FDA-approved geographic atrophy treatments presents a complex clinical decision without clear superiority ...

At the 2025 annual scientific meeting of the American Society of Retina Specialists (ASRS), Jay Chhablani, MD, Vice Chair at University of Pittsburgh Medical Center gave a presentation titled, "Safety ...